Long-Term Effect of Varenicline (Chantix®) in Four Ataxic Patients: Prolonged Symptomatic Benefit Following Drug Discontinuation

  • Theresa A. Zesiewicz
  • , Kelly L. Sullivan
  • , A. Miller
  • , L. E. Dempsey
  • , Israt Jahan
  • , L. Wecker

Research output: Contribution to conference › Presentation

Abstract

This presentation was given at the World Congress on Parkinson’s Disease and Related Disorders.
Original languageAmerican English
StatePublished - Dec 13 2009
EventWorld Congress on Parkinson’s Disease and Related Disorders - Miami Beach, FL
Duration: Dec 13 2009 → …

Conference

ConferenceWorld Congress on Parkinson’s Disease and Related Disorders
Period12/13/09 → …

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Disciplines

  • Public Health
  • Epidemiology

Keywords

  • Ataxic patients
  • Chantix
  • Drug discontinuation
  • Long-term effect
  • Prolonged symptomatic benefit
  • Varenicline

Fingerprint

Dive into the research topics of 'Long-Term Effect of Varenicline (Chantix®) in Four Ataxic Patients: Prolonged Symptomatic Benefit Following Drug Discontinuation'. Together they form a unique fingerprint.
View full fingerprint

Cite this